Investors in antibiotic developer Cempra Inc overreacted on Oct. 16, pushing the stock down more than 30% after positive late-stage trial data came back slightly tarnished – leaving others an opportunity to buy the biotech on the cheap.
Cempra announced before the opening bell Friday morning the topline results from its Phase III trial of the antibiotic solithromycin...